Skip to content

September 2026

This Month in Cervical Cancer Research

September's cervical cancer research ranged from long-term questions about treatment to the practical work of reaching women who have never been screened. For people with advanced or recurrent disease, studies explored new drug combinations matched to tumor genetics, the best timing for immunotherapy alongside chemoradiation, and a blood test that may one day flag a returning cancer early. Prevention research was especially strong: real-world data from Brazil showed falling rates of precancer and cancer among young women a decade after HPV vaccination began, and several studies showed how self-collected HPV tests can bring screening to pregnant women, busy households, and remote communities. Running through the month was the field's defining tension: cervical cancer is largely preventable, yet women in low- and middle-income countries, women living with HIV, and underserved communities in wealthy countries still carry most of its burden. Many of this month's papers asked not whether the tools work, but how to get them to everyone.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

New treatment strategies are expanding options for advanced and recurrent cervical cancer

For people whose cervical cancer has spread or come back, the list of treatment options keeps growing, and researchers are now asking sharper questions about who benefits most, and when.

  • If your recurrent or metastatic cervical cancer carries a PIK3CA mutation (one of the most common genetic changes in cervical tumors), an early study suggests that pairing immunotherapy with a targeted pill may shrink tumors more often than standard treatment. Chang and colleagues pooled 55 patients from two prospective Chinese trials and records at Fujian Cancer Hospital, comparing an immune checkpoint inhibitor (a drug that releases a brake on the immune system so it can attack cancer) plus a tyrosine kinase inhibitor, or TKI, with conventional treatment. Tumors shrank in 85% of the combination group versus 29% of the comparison group, and the cancer was held in check for a median of 21 months versus 9 months, although overall survival did not differ significantly. Side effects such as high blood pressure, rash, and thyroid changes were more common but manageable; because the study was small and not randomized, larger trials are needed. (Read the full paper)
  • A new review helps make sense of the crowded pipeline of drugs for recurrent and metastatic cervical cancer by sorting them by how they work and how far along they are, from approved treatments to early laboratory candidates. The authors cover checkpoint inhibitors; bispecific antibodies such as cadonilimab, which blocks two immune brakes (PD-1 and CTLA-4) at once; antibody-drug conjugates, or ADCs, which are cancer-seeking antibodies joined to a chemotherapy payload that deliver it directly to tumor cells; therapeutic HPV vaccines; and engineered immune cell therapies. They also argue that because access to new drugs differs widely between countries, the point in treatment at which a drug is offered may matter as much as whether it is approved. (Read the full paper)
  • For people with locally advanced cervical cancer, meaning disease that has grown beyond the cervix but has not spread to distant organs, a review from Xuancheng Hospital of Wannan Medical University in China tackles a puzzle: why adding pembrolizumab to chemoradiation improved survival in the KEYNOTE-A18 trial while adding durvalumab did not in the CALLA trial. Drawing on studies that sampled tumors and blood before, during, and after treatment, the authors describe how the immune environment shifts over the course of chemoradiation. They propose, explicitly as a hypothesis rather than a finding, that immunotherapy given early, during an immune "priming window," might work better than the same drug given afterward, and they outline the trials and biomarker studies needed to test this. (Read the full paper)
  • A blood test may one day help doctors watch for cervical cancer coming back without invasive procedures. Van Arsdale and colleagues, writing in eLife, found that fragments of DNA where HPV has fused into a person's own genes can be detected in the blood of some people with cervical cancer, and that these fragments were found more often, at diagnosis or six months after treatment, in women whose cancer later recurred. They also found that cancers caused by HPV types outside the group that includes HPV16 recurred more often, a pattern confirmed in a large public cancer database. This is retrospective, early-stage research, but it points toward a simple, noninvasive way to monitor people after treatment. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

HPV vaccination is preventing precancer, and new research shows how to reach more young people

HPV vaccination is the first line of defense against cervical cancer, and this month brought fresh real-world evidence that it works, along with practical lessons on reaching the girls and families who are still being missed.

  • Twelve years after Brazil added HPV vaccination to its public health system, young women are developing fewer precancers and cancers. Carneiro and colleagues compared screened women under 25 (those eligible for the vaccine) in 2025 with the same age group in 2010 to 2012, and found significantly lower rates of high-grade precancer (CIN2 or worse, and CIN3 or worse) and of invasive cervical cancer nationwide. The gains were uneven, though: reductions were significant in the Southeast, South, and Midwest, but not in the North, a reminder that vaccine benefits follow vaccine access. The authors also saw hints of indirect protection in some older, unvaccinated age groups; because this was an ecological comparison of population data, it shows trends rather than proving cause. (Read the full paper)
  • Countries may be able to eliminate cervical cancer faster than expected by designing vaccination programs to stop HPV from spreading, not only to protect individuals. In a review, Dillner, of the Karolinska Institutet's Center for Cervical Cancer Elimination in Sweden, explains that because the vaccine prevents infection itself, it creates herd immunity, and the coverage needed to drive HPV toward extinction is moderate, especially when boys are vaccinated too. The review highlights catch-up vaccination of adolescents, single-dose schedules, and tracking HPV infection rates as ways to speed progress, and notes that screening becomes simpler once new infections stop. (Read the full paper)
  • As Pakistan prepared for its first national HPV vaccine rollout, a qualitative study (based on interviews and focus groups) in Punjab asked the people whose trust the campaign would need: adolescent girls, parents, teachers, health workers, and religious scholars. Barriers included fear of side effects, misinformation spread on social media, some religious perceptions, family decisions made by male relatives, and long waits at clinics. Facilitators were just as telling: counseling from health workers, trust in schools, supportive family and community norms, door-to-door outreach, and, for some, religious belief itself. The authors call for culturally sensitive, trust-building approaches that go beyond a purely clinical message. (Read the full paper)
  • In Japan, where active government recommendation of the HPV vaccine was paused from 2013 to 2022, medical students may be effective messengers for teenagers. Nakajima and colleagues ran one-hour, interactive sessions led by medical students in junior and senior high schools between 2022 and 2024, using quizzes, role-play, and student-made social media messages. Among 248 previously unvaccinated students who completed follow-up, 7.5% of girls and 0.9% of boys reported getting vaccinated within two weeks, and students who intended to get vaccinated understood the material better. The study had no comparison group, so it is a promising early signal rather than proof. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Self-sampling, smarter triage, and digital tools are reshaping cervical screening

Screening finds precancer before it becomes cancer, and this month's research focused on making it easier to do, easier to interpret, and easier to reach.

  • Pregnancy can be a powerful moment to catch up on cervical screening when women can collect their own sample. At Westmead Hospital in Sydney, Australia, Wang and colleagues built self-collected HPV testing (a simple vaginal swab, no speculum exam needed) into routine prenatal care for an under-screened, culturally diverse population. Between February 2024 and July 2025, 94% of the pregnant women who were offered the test accepted it, and screening among those due rose from 3% before the program to 65%. Being born overseas or needing an interpreter was not a barrier, and seven women were found to have high-grade precancer needing treatment. (Read the full paper)
  • Bringing screening to the doorstep can reach women who would otherwise never be tested. In an urban area of Nepal, where national screening coverage is about 16%, trained community health workers went door to door offering education and home HPV self-sampling kits to women aged 30 to 60. Of those approached, 64% took part; about 10% tested positive for high-risk HPV and were linked to follow-up exams, colposcopy, and treatment, and six precancers were found, including one CIN3. The authors conclude the approach is feasible and connects women to care, not just to a test result. (Read the full paper)
  • A test that reads chemical tags on DNA may help decide which women with a positive HPV test truly need further evaluation, a step called triage. Pooling eight studies of nearly 7,500 HPV-positive women, Qi and colleagues found that a two-gene DNA methylation test (PAX1/JAM3) correctly identified 81% of women with high-grade precancer (CIN2 or worse) and gave a correct negative result for 95% of women without it. Tests like this could help reduce unnecessary colposcopies, and the authors see a potential role for this one as a triage tool. (Read the full paper)
  • Artificial intelligence may support health workers who screen with VIA (visual inspection with acetic acid, where a provider looks at the cervix after applying vinegar), but real-world conditions matter. Koot and colleagues tested an AI decision-support tool built on an adapted smartphone in rural clinics in Bangladesh and Uganda. The tool worked well in the lab but less well in the field; clinics sometimes lacked steady electricity or internet, and neither country yet had a policy governing AI in health care. Women accepted the device when their privacy was protected but tended to trust the health worker's judgment more, an important lesson for anyone designing digital tools for screening. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Women's own voices show what helps and what gets in the way of cervical screening

Some of the most useful screening research this month came directly from women themselves, explaining in their own words what makes screening feel possible, or not.

  • In rural Kilimanjaro, Tanzania, where 88% of women aged 30 to 49 have never been screened, women and health care providers described what stands in the way. In six focus groups with 54 women and twelve interviews with providers, Machange and colleagues heard about limited knowledge, misconceptions, fear of pain and of a positive result, hard-to-reach services, and too few trained staff. The strongest facilitator was social support from families, peers, community leaders, and providers, which suggests that screening programs work best when they bring communities along. (Read the full paper)
  • Misconceptions remain a major barrier in Wakiso District, Uganda, according to focus groups with 60 women and interviews with local health officials. Some women believed cervical cancer was caused by contraceptive methods such as IUDs and pills, by poor hygiene, or by witchcraft, and some feared that screening would remove the cervix. Women who had been screened often described positive experiences, but concerns about pain, discomfort, and lack of privacy were common. The authors call for culturally sensitive education and respectful, accessible services. (Read the full paper)
  • Even in a country with an established screening program, how women are treated shapes whether they come back. A nationwide survey of nearly 5,200 women in Hungary found that about 60% had been screened in the past year and 3.5% never had. Women who talked about screening with people in their lives were more likely to attend regularly, while negative experiences with health care, cost, fear of a diagnosis, and lack of time kept others away. The findings point to physician communication and the screening experience itself as levers for improving participation. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Better ways to treat precancer and confirm it is gone

For people diagnosed with CIN, meaning precancerous changes in cervical cells graded 1 to 3, this month's research focused on avoiding both overtreatment and undertreatment, and on cutting through misleading claims.

  • After treatment for high-grade precancer (CIN2 or CIN3), a negative HPV test is a reliable sign that the precancer is gone. In a systematic review of 15 studies including nearly 22,000 treated women, Timis and colleagues found that high-grade disease came back in roughly 2% to 7% of women in most studies, and that HPV testing was generally better than a Pap test at detecting it. A negative HPV test correctly ruled out remaining disease 98% to 100% of the time. The authors say this supports lighter follow-up after a negative test, but not an immediate return to routine screening. (Read the full paper)
  • "See-and-treat," where a woman is treated with a LEEP (loop electrosurgical excision procedure, which removes abnormal tissue with a thin wire loop) at her first colposcopy visit, saves time but can lead to unnecessary treatment. Reviewing six guidelines and 39 studies, Damen and colleagues at Cochrane Netherlands found little agreement on which visual signs should guide that decision, and overtreatment rates ranged widely, from about 6% to 73% depending on the study and lesion grade. About 8% of women whose colposcopy looked normal turned out to have CIN3 or cancer. The findings matter for anyone weighing same-day treatment. (Read the full paper)
  • Many products are marketed as cures for HPV infection, but none has been proven to clear it. A statement from the International Papillomavirus Society, led by Arroyo Mühr of the Karolinska Institutet's International HPV Reference Center in Sweden, reviewed the evidence for topical creams, oral supplements, probiotics, vaginal gels, therapeutic vaccines, and other options. Some treatments work for specific lesions, and topical 5-fluorouracil has helped CIN regress in randomized trials in certain settings, but no therapy reliably eliminates the underlying infection. The statement sets standards for testing future treatments and cautions against spending money on unproven products. (Read the full paper)
  • Researchers are looking at the vaginal microbiome, the community of bacteria living there, to understand why some low-grade cervical changes clear on their own while others progress. Studying 90 women with low-grade lesions, Stosic and colleagues at the Karolinska Institutet found that overall bacterial diversity did not differ between lesions that regressed and those that progressed, but a model combining age with bacterial types and their predicted functions modestly improved the ability to tell the two apart. This is early, exploratory work that could one day help personalize follow-up. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Women living with HIV carry a higher risk, and research is tailoring prevention and care to them

Women living with HIV face a much higher risk of cervical cancer, and this month's research highlighted both the scale of that risk and the gaps in care that follow it.

  • Cervical cancer is the most common of the cancers linked to advanced HIV, and the burden falls heaviest on Africa. In a global modeling study, Meng and colleagues estimated that in 2022 about 102,000 cases of AIDS-defining cancers (cervical cancer, non-Hodgkin lymphoma, and Kaposi sarcoma) were attributable to HIV, and cervical cancer made up 53% of all cases of these cancers. In East and Southern Africa, more than a quarter of these cancers were linked to HIV, and countries with lower human development scores carried more of the burden. The authors call for expanded HIV treatment and cancer prevention working hand in hand. (Read the full paper)
  • Being screened once is not enough for women living with HIV, who need regular follow-up, yet many never return. Among 2,030 women living with HIV first screened in Moshi, Tanzania, between 2019 and 2021, only one in three came back for a follow-up screening, and only about one in five of those returned on time. Women first screened at outreach events were much less likely to return, while those screened at private facilities or told of an abnormal result were more likely to. The findings suggest that stronger links between outreach screening and ongoing care could help. (Read the full paper)
  • Nearly half of women living with HIV at a treatment center in Kinshasa, Democratic Republic of the Congo, carried a high-risk HPV type. Among 436 women aged 25 to 65 on antiretroviral therapy, 47.7% tested positive, and about one in four of those had HPV16 or HPV18, the types most strongly linked to cancer; other high-risk types were more common. Advanced HIV, an unsuppressed viral load, and fewer than two years on HIV treatment were each linked to infection. The authors note that vaccines covering more HPV types could help protect this population. (Read the full paper)
  • Women living with HIV have been largely left out of the major immunotherapy trials for cervical cancer, so it is unclear how well these treatments work for them. In a review, Huang and colleagues describe how HIV may change the immune environment around cervical tumors, through chronic inflammation, exhausted immune cells, and disruption of the cervical lining, and why standard markers such as PD-L1 levels or CD4 counts may not tell the whole story. They propose a framework, not yet validated, to guide more inclusive trials. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Closing the global equity gap remains central to eliminating cervical cancer

The tools to eliminate cervical cancer exist; this month's research focused on who is getting them, who is not, and why.

  • Global efforts have funded vaccines for girls far better than care for the women who are already at risk, and that imbalance has real consequences. In a perspective, Sriram, of the University of North Texas, notes that the World Health Organization's elimination strategy rests on three targets: vaccinate 90% of girls, screen 70% of women, and treat 90% of those with disease. Only vaccination is backed by a global pooled purchasing and co-financing mechanism; screening, treatment of precancer, and cancer care depend on national budgets or out-of-pocket payment. Because the women dying of cervical cancer today were born too early to be vaccinated, the author argues, this gap is a structural unfairness, and the paper proposes four financing remedies. (Read the full paper)
  • India, which carries a large share of the global cervical cancer burden, already has the tools for elimination; the challenge now is delivery at scale. Drawing on a 2025 International Papillomavirus Society session and the published literature, Balasubramani and colleagues identified five priorities: building trust-driven demand, strengthening providers' ability to recommend vaccination, designing screening around completing the full care pathway, embedding community engagement in services, and investing in governance, financing, and digital registries. Trust, they conclude, is the thread that links awareness to action. (Read the full paper)
  • In the United States, cervical cancer deaths have fallen by more than half since 1999, but not equally. Using national death records from 1999 to 2023, Liu and colleagues found the age-adjusted death rate dropped from 4.37 to 2.09 per 100,000 women. Rates remained consistently higher in the South, among non-Hispanic Black women, and in rural (nonmetropolitan) areas, and the highest-burden states had rates two to four times those of the lowest. (Read the full paper)
  • Finding precancer is only half the job; women also need to get to treatment. In a review of 2022 Pap test results from 19 public clinics in Cape Town, South Africa, about two-thirds of women with high-grade abnormal results had a follow-up biopsy within two years, well below the WHO target of treating 90% of women with disease. Follow-up rates varied from 43% to 88% between clinics and were unrelated to distance from the hospital, suggesting that communication, recall, and referral systems are where improvements are most needed. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Survivorship research is mapping the needs that follow treatment

As more people survive cervical cancer, attention is turning to the physical, emotional, and practical needs that continue after treatment ends.

  • Nearly everyone treated for breast or cervical cancer at a major cancer center in Hawassa, Ethiopia, reported at least one unmet supportive care need. Among 349 patients, needs spanned physical and daily living, psychological health, sexual health, patient care, and health information. Having health insurance was linked to fewer unmet needs, while relying on traditional or spiritual healing was linked to more. The authors call for better patient-provider communication, stronger social support, and spiritual care built into cancer services in low-resource settings. (Read the full paper)
  • Many cervical cancer survivors may be able to use menopausal hormone therapy safely to relieve symptoms such as hot flashes, vaginal dryness, and sleep problems. A position paper from the FIGO Committee on Women at Menopausal Age reviewed the evidence across gynecologic cancers and concluded that systemic hormone therapy may be suitable for carefully chosen survivors of cancers that are not hormone-dependent, including most cervical cancers. Vaginal and non-hormonal options remain important for others, and the authors emphasize the needs of younger women in low- and middle-income countries who often face treatment-induced menopause with limited survivorship support. If menopause symptoms are affecting your life, this is worth raising with your care team. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

General and basic-science research continues to map how cervical tumors grow and resist treatment

This month's work in this area is mostly early-stage laboratory, genetic, and modeling research, including studies of rare subtypes such as cervical adenocarcinoma and neuroendocrine carcinoma. It is listed here so researchers and curious readers can find it.

Check the citations section for a comprehensive list of publications associated with this topic.

What Does This Mean for Me?

If you are living with advanced or recurrent cervical cancer. Treatment options are expanding, and new research is exploring how to match therapies to the genetics of your tumor, such as a PIK3CA mutation, and how to time immunotherapy alongside chemoradiation. Much of this work is early, so it is a reason to ask questions rather than to change course on your own. Consider asking your care team: Has my tumor had genetic or biomarker testing, and could the results open other treatment options? Am I a candidate for immunotherapy, an antibody-drug conjugate, or a clinical trial? What follow-up plan will help catch any recurrence early?

If you have had an abnormal screening result or treatment for precancer. This month's research is reassuring: after treatment for high-grade precancer, a negative HPV test is a strong sign the abnormal cells are gone. If you are offered same-day "see-and-treat" care, it is reasonable to ask how confident your provider is that treatment is needed, especially if you hope to have children. Be wary of supplements, gels, or other products marketed as HPV cures; none has been shown to clear the infection. Questions to ask: What does my HPV test result mean for my follow-up schedule? Is treatment needed now, or can we watch and retest?

If you are thinking about prevention for yourself or your family. HPV vaccination works, and real-world data from Brazil show it is already lowering precancer and cancer rates among young women. If you have a child aged 9 to 14, ask their doctor about the HPV vaccine; catch-up vaccination may also be available for older teens and young adults. If you are due for screening and a speculum exam has kept you away, ask whether self-collected HPV testing is available where you live. If you are living with HIV, ask about a screening schedule designed for you, since more frequent follow-up is recommended.

If you are a cervical cancer survivor. Life after treatment can bring new challenges, from menopause symptoms to emotional and practical needs. Expert guidance this month suggests that many cervical cancer survivors may safely use menopausal hormone therapy, so symptoms like hot flashes, vaginal dryness, or poor sleep are worth raising. Ask your care team: Is hormone therapy an option for me? What support is available for my emotional health, sexual health, and day-to-day needs?

Clinical trials are how every advance described here became possible, and many are open to people with cervical cancer at every stage. Ask your care team whether a trial might be right for you, or explore options at ClinicalTrials.gov. OCRA's patient support programs and resources at ocrahope.org can help you find information, connect with others, and navigate care.

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

The citations below are grouped to match the sections above. "Directly referenced" papers are the ones summarized in that section; the remaining entries are on-topic papers that were either not discussed above or are behind access restrictions.

New treatment strategies are expanding options for advanced and recurrent cervical cancer

Directly referenced:

1. Chang L, et al. "Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation." PLoS One. September 29, 2026. PMID 42809552. https://doi.org/10.1371/journal.pone.0350571

2. Yang C, et al. "Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them." Front Immunol. September 7, 2026. PMID 42769609. https://doi.org/10.3389/fimmu.2026.1948148

3. Yang C, et al. "Immune remodeling during cervical cancer chemoradiotherapy: temporal biomarkers and the timing of checkpoint blockade." Front Immunol. September 3, 2026. PMID 42756032. https://doi.org/10.3389/fimmu.2026.1947595

4. Van Arsdale AR, et al. "Serum, cell-free, HPV-human DNA junction detection and HPV typing for predicting and monitoring cervical cancer recurrence." Elife. September 9, 2026. PMID 42713958. https://doi.org/10.7554/eLife.105741

Additional open-access citations:

5. Markus M, et al. "FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer." BMC Med Imaging. September 18, 2026. PMID 42760525. https://doi.org/10.1186/s12880-026-02772-8 (open access, PET/CT response and survival after chemoradiation)

6. Alsalloum A, et al. "Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress." Front Immunol. September 16, 2026. PMID 42819744. https://doi.org/10.3389/fimmu.2026.1897025 (open access, review of immunotherapy for HPV-associated cancers)

7. Li W, et al. "Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance." Front Immunol. September 8, 2026. PMID 42774775. https://doi.org/10.3389/fimmu.2026.1925452 (open access, immune biomarkers for checkpoint blockade)

8. Yordanov A, et al. "Integrated Immune Escape in Cervical Cancer: HLA-I Dysfunction and Immune Checkpoint Signaling." Int J Mol Sci. September 9, 2026. PMID 42794439. https://doi.org/10.3390/ijms27188009 (open access, review of immune escape mechanisms)

9. Pan YX, et al. "Prognostic impact of HLA-G expression in cervical squamous cell carcinoma: correlation with PD-L1 and CD8-positive tumor infiltrating lymphocytes." Front Immunol. September 11, 2026. PMID 42798542. https://doi.org/10.3389/fimmu.2026.1957106 (open access, HLA-G and PD-L1 in squamous cell carcinoma)

10. Jin H, et al. "Successful treatment of massive stage IIIB cervical cancer with a spindle cell component: A case report." Medicine (Baltimore). September 11, 2026. PMID 42736813. https://doi.org/10.1097/MD.0000000000050727 (open access, case report, stage IIIB disease with spindle cell component)

11. Jin Y, et al. "Translational Progress of Inorganic Nanotheranostic Platforms for Gynecologic Malignancies: A Narrative Review of Endometrial, Ovarian, and Cervical Cancer Focusing on Fertility Preservation, Biosafety, and Industrial Translation." Int J Nanomedicine. September 16, 2026. PMID 42769022. https://doi.org/10.2147/IJN.S642254 (open access, review of nanomedicine across gynecologic cancers)

Related citations, access restricted:

12. Hasegawa K, et al. "Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial." JAMA Oncol. September 10, 2026. PMID 42720936. https://doi.org/10.1001/jamaoncol.2026.3547 (free to read, no reuse license)

13. Manning WB, et al. "IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers." Cancer. September 15, 2026. PMID 42745396. https://doi.org/10.1002/cncr.70611 (free to read, no reuse license)

14. Yacob SM, et al. "Outcomes and patterns of management of metastatic/recurrent cervical carcinoma in Malaysia: A single institutional observational cohort study." Med J Malaysia. September 2026. PMID 42813479. https://pubmed.ncbi.nlm.nih.gov/42813479/ (license unconfirmed)

15. Shimizu A, et al. "Real-World Outcomes of Weekly Paclitaxel-Carboplatin-Based Chemoradiotherapy Versus Cisplatin-Based Chemoradiotherapy for FIGO Stage IB2-IVA Cervical cancer: A Retrospective Observational Study." J Obstet Gynaecol Res. September 2026. PMID 42706612. https://doi.org/10.1111/jog.70489 (free to read, no reuse license)

16. Ahn C, et al. "Intrathecal Chemotherapy Through Ommaya Reservoir in Leptomeningeal Metastasis From Cervical Cancer: A Rare Case Report and Literature Review." J Obstet Gynaecol Res. September 2026. PMID 42695575. https://doi.org/10.1111/jog.70490 (license unconfirmed)

17. Sugita C, et al. "[Cervical cancer metastasis to the lumbosacral spinal root: a case report]." Rinsho Shinkeigaku. September 2026. PMID 42572293. https://doi.org/10.5692/clinicalneurol.cn-002272 (license unconfirmed)

18. Fusegi A, et al. "Surgical de-escalation in early-stage cervical cancer: current evidence and future perspectives." Jpn J Clin Oncol. September 9, 2026. PMID 42284218. https://doi.org/10.1093/jjco/hyag092 (subscription access)

19. Casarin J, et al. "Surgical volume, structural quality, and compliance with European Society of Gynaecological Oncology quality indicators in endometrial and cervical cancer: a regional cross-sectional assessment." Int J Gynecol Cancer. September 2026. PMID 42501475. https://doi.org/10.1016/j.ijgc.2026.104847 (subscription access)

20. Bahrehmand K, et al. "[The role of sentinel lymph node biopsy in the management of gynecologic cancers: current evidence and institutional experience]." Magy Onkol. September 2026. PMID 42731005. https://pubmed.ncbi.nlm.nih.gov/42731005/ (free to read, no reuse license)

HPV vaccination is preventing precancer, and new research shows how to reach more young people

Directly referenced:

21. Carneiro FP, et al. "Impact of HPV vaccination on cervical precancer and invasive cervical cancer twelve years after vaccine introduction in the Brazilian Public Health System." J Infect Public Health. September 2026. PMID 42600200. https://doi.org/10.1016/j.jiph.2026.103326

22. Dillner J. "Optimising Human Papillomavirus Vaccination Strategies for Faster Cervical Cancer Elimination." Acta Paediatr. September 5, 2026. PMID 42699989. https://doi.org/10.1111/apa.70756

23. Noreen K, et al. "HPV vaccine uptake in Pakistan: A qualitative study to identify barriers and facilitators before the first HPV national rollout." Hum Vaccin Immunother. September 3, 2026. PMID 42692950. https://doi.org/10.1080/21645515.2026.2721105

24. Nakajima K, et al. "Near-peer education by medical students and its association with HPV vaccination knowledge and attitudes among Japanese adolescents: An exploratory intervention study." Hum Vaccin Immunother. September 2, 2026. PMID 42687414. https://doi.org/10.1080/21645515.2026.2724650

Additional open-access citations:

25. Burdier FR, et al. "Elimination of HPV-associated cancers: universal HPV vaccination and the role of anal screening - a meeting report." BMC Proc. September 22, 2026. PMID 42768360. https://doi.org/10.1186/s12919-026-00393-1 (open access, meeting report on gender-neutral vaccination and anal screening)

26. Omidimorad A, et al. "Human papillomavirus (HPV) and HPV vaccine awareness in Indigenous communities in Northwest Territories, Canada." PLoS One. September 3, 2026. PMID 42691150. https://doi.org/10.1371/journal.pone.0357586 (open access, HPV vaccine awareness in Indigenous communities, Canada)

27. Zhou X, et al. "Knowledge and attitudes of medical students about human papillomavirus (HPV) and HPV vaccine: A cross-sectional survey in Inner Mongolia, China." Hum Vaccin Immunother. September 27, 2026. PMID 42802652. https://doi.org/10.1080/21645515.2026.2738975 (open access, HPV knowledge among medical students, China)

28. Lubanga AF, et al. "Protect her future: Lessons learned from a school and community engagement initiative for HPV vaccine awareness in Lilongwe, Malawi." Hum Vaccin Immunother. September 7, 2026. PMID 42703762. https://doi.org/10.1080/21645515.2026.2727812 (open access, youth-led vaccine awareness initiative, Malawi)

29. Li X, et al. "Guardians' willingness to vaccinate primary and secondary school girls against human papillomavirus and associated factors in ethnic autonomous prefectures of Qinghai Province, China: A cross-sectional study based on the Health Belief Model and Theory of Planned Behavior." Hum Vaccin Immunother. September 1, 2026. PMID 42678389. https://doi.org/10.1080/21645515.2026.2725492 (open access, caregiver willingness to vaccinate, Qinghai, China)

Related citations, access restricted:

30. Wieland U, et al. "[Vaccine prevention of HPV-associated diseases]." Dermatologie (Heidelb). September 11, 2026. PMID 42726205. https://doi.org/10.1007/s00105-026-05786-z (subscription access)

31. de Campos MR, et al. "Knowledge and Perception of Human Papillomavirus in Quilombola Communities in Northeast Brazil." Hisp Health Care Int. September 2026. PMID 41118537. https://doi.org/10.1177/15404153251383132 (subscription access)

32. Cordoba-Sanchez V, et al. "A cluster-randomized trial of the school-based 'Superprotegidas' behavioral intervention to improve HPV vaccination uptake in Colombian girls." Vaccine. September 17, 2026. PMID 42753387. https://doi.org/10.1016/j.vaccine.2026.129172 (restricted license, CC BY-NC-ND 4.0)

33. Gong J, et al. "Effects of a Message-Framing Video Intervention on Maternal Vaccine Confidence Regarding HPV Vaccination for Daughters: A Quasi-Experimental Study Among Mothers With Cervical Intraepithelial Neoplasia." Public Health Nurs. September 2026. PMID 42489414. https://doi.org/10.1111/phn.70162 (free to read, no reuse license)

34. Butler TL, et al. "Aboriginal and Torres Strait Islander adolescent and parent perspectives on human papillomavirus vaccination through the School Immunisation Program in Queensland, Australia: a qualitative study." Vaccine. September 28, 2026. PMID 42805053. https://doi.org/10.1016/j.vaccine.2026.129170 (license unconfirmed)

35. Sell H, et al. "Factors influencing human papillomavirus school-based immunization in Alberta: a qualitative inquiry." Can J Public Health. September 24, 2026. PMID 42786307. https://doi.org/10.17269/s41997-026-01250-6 (restricted license, CC BY-NC-ND 4.0)

36. Lim MSH, et al. "A Cross-Sectional Study of Knowledge, Attitudes, and Perceptions toward HPV Vaccination Among Undergraduate Students Studying in Sarawak, Malaysia." Asian Pac J Cancer Prev. September 1, 2026. PMID 42808405. https://doi.org/10.31557/APJCP.2026.27.9.3365 (license unconfirmed)

Self-sampling, smarter triage, and digital tools are reshaping cervical screening

Directly referenced:

37. Wang M, et al. "Implementation of self-collected cervical screening in an under-screened, culturally and linguistically diverse antenatal population: a quality improvement study." BMJ Open Qual. September 29, 2026. PMID 42810763. https://doi.org/10.1136/bmjoq-2026-004525

38. Maharjan S, et al. "Community-Based HPV Self-Sampling to Enhance Access to Cervical Cancer Prevention: A Continuum-of-Care Model from Urban Nepal." Curr Oncol. September 5, 2026. PMID 42782885. https://doi.org/10.3390/curroncol33090539

39. Qi L, et al. "Meta-analysis of PAX1/JAM3 methylation performance in high-risk HPV-positive women." Medicine (Baltimore). September 18, 2026. PMID 42760652. https://doi.org/10.1097/MD.0000000000050757

40. Koot J, et al. "Applying an AI Decision Support Device During Cervical Cancer Screening in Bangladesh and Uganda: Implementation Study." JMIR Form Res. September 3, 2026. PMID 42691425. https://doi.org/10.2196/81493

Additional open-access citations:

41. Eroğlu ÖO, et al. "Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study." J Med Internet Res. September 22, 2026. PMID 42772748. https://doi.org/10.2196/98131 (open access, large language models and abnormal screening management)

42. Murray GL, et al. "A droplet digital PCR assay targeting 16 human papillomavirus genotypes." Access Microbiol. September 2, 2026. PMID 42688888. https://doi.org/10.1099/acmi.0.001166.v3 (open access, laboratory HPV genotyping assay)

43. Donkoh ET, et al. "Development of a multiplex quantitative real-time PCR (qPCR) assay for simultaneous detection of Schistosoma haematobium and high-risk human papillomaviruses." PLoS Negl Trop Dis. September 11, 2026. PMID 42726901. https://doi.org/10.1371/journal.pntd.0014694 (open access, combined HPV and schistosomiasis test, Ghana)

44. Zhao Q, et al. "From HPV genotypes to cervical lesion burden: public health-relevant heterogeneity across 1.29 million screening records in Guangdong, China." Front Public Health. September 17, 2026. PMID 42824128. https://doi.org/10.3389/fpubh.2026.1897790 (open access, HPV genotypes across 1.29 million screening records, China)

45. Carvalho TS, et al. "Primary and secondary prevention of cervical cancer during the COVID-19 pandemic in Sao Paulo State, Brazil." Rev Inst Med Trop Sao Paulo. September 18, 2026. PMID 42788601. https://doi.org/10.1590/S1678-9946202668064 (open access, vaccination and screening during COVID-19, Brazil)

46. Spencer ER, et al. "Impact of menopausal status on human papillomavirus detection and cervical neoplasia in middle-aged Senegalese women." PLoS One. September 11, 2026. PMID 42726759. https://doi.org/10.1371/journal.pone.0358080 (open access, menopause and HPV detection, Senegal)

47. Effah K, et al. "Cervical leukoplakia in Ghana: Unveiling diagnostic challenges and informing low-resource screening strategies." PLoS One. September 9, 2026. PMID 42715241. https://doi.org/10.1371/journal.pone.0345847 (open access, cervical leukoplakia in screening, Ghana)

48. Li H, et al. "Clinical significance of Chlamydia trachomatis and HPV coinfection across cervical lesion severity: a 10-year retrospective study in Southern China." Front Cell Infect Microbiol. September 11, 2026. PMID 42798386. https://doi.org/10.3389/fcimb.2026.1832343 (open access, chlamydia and HPV coinfection, China)

Related citations, access restricted:

49. Zulfikaroglu E. "Cervical cancer screening strategies in women 65 years and older in the human papillomavirus era: A systematic review and meta-analysis of human papillomavirus-based testing and self-sampling approaches." Int J Gynaecol Obstet. September 2026. PMID 41817023. https://doi.org/10.1002/ijgo.70962 (free to read, no reuse license)

50. Bonde J, et al. "Health Care Policy Implementation Trial of Primary Human Papillomavirus-Based Cervical Screening in Denmark." Int J Cancer. September 2026. PMID 42046158. https://doi.org/10.1002/ijc.70502 (license unconfirmed)

51. Xu Y, et al. "DNA Methylation Testing in Cervical Cancer: A Triage Tool for HPV-Based Screening and Post-Treatment Surveillance." J Obstet Gynaecol Res. September 2026. PMID 42681848. https://doi.org/10.1111/jog.70473 (free to read, no reuse license)

52. Sultana F, et al. "Clinical Evaluation of miR-135b-5p and miR-21-5p Expression on Self-Collected Cervical Swab Samples for Triaging HR-HPV-Positive High-Grade Preneoplastic Lesions in India." Genet Test Mol Biomarkers. September 24, 2026. PMID 42784467. https://doi.org/10.1177/19450265261491098 (subscription access)

53. Dalvi DD, et al. "Regional Diversity of Human Papillomavirus Genotypes in Southeastern Brazil: Implications for Cervical Cancer Screening." J Med Virol. September 2026. PMID 42762472. https://doi.org/10.1002/jmv.71140 (subscription access)

54. Deshmukh VN, et al. "HPV genotype distribution and associated risk factors in women from Karad, Maharashtra: A molecular characterisation study." Indian J Med Res. September 2026. PMID 42690849. https://doi.org/10.25259/IJMR_4_2026 (restricted license, CC BY-NC-SA 4.0)

55. Yang YJ, et al. "[Exploration of a cervical cancer prevention and treatment model in low-resource regions supported by emerging technologies]." Zhonghua Yu Fang Yi Xue Za Zhi. September 6, 2026. PMID 42736162. https://doi.org/10.3760/cma.j.cn112150-20251103-01042 (license unconfirmed)

56. Yang Z, et al. "Colorimetric analysis of metabolic biomarkers from unprocessed urine for rapid, at-home diagnosis of cervical cancer." Chem Commun (Camb). September 22, 2026. PMID 42638531. https://doi.org/10.1039/d6cc03906e (subscription access)

Women's own voices show what helps and what gets in the way of cervical screening

Directly referenced:

57. Machange RF, et al. "Perspectives of women and healthcare providers on facilitators and barriers to cervical cancer screening in the rural Kilimanjaro region Tanzania: a qualitative study." Glob Health Action. September 28, 2026. PMID 42802903. https://doi.org/10.1080/16549716.2026.2735552

58. Bulamba RM, et al. ""Even with one Man, but with many women, you can get cervical cancer": Qualitative exploration of women's perceptions and experiences of cervical cancer screening in Uganda: A community-based study." PLOS Glob Public Health. September 18, 2026. PMID 42758761. https://doi.org/10.1371/journal.pgph.0007256

59. Tóth R, et al. "Beyond Access and Awareness: The Role of Patient Experience and Physician Communication in Cervical Cancer Screening Participation in Hungary." Cancers (Basel). September 16, 2026. PMID 42794965. https://doi.org/10.3390/cancers18182999

Additional open-access citations:

60. Spriņģe L, et al. "Women's compliance with cervical cancer screening recommendations and associated barriers to participation: A cross-sectional analysis." PLoS One. September 10, 2026. PMID 42721157. https://doi.org/10.1371/journal.pone.0357819 (open access, screening compliance and awareness, Latvia)

61. Nichol B, et al. "Behaviourally informed text message reminders to increase cervical screening attendance in people with severe mental illness: the OPTIMISE pilot randomised controlled trial." BMJ Open. September 11, 2026. PMID 42731841. https://doi.org/10.1136/bmjopen-2026-122934 (open access, text reminders for people with severe mental illness, pilot trial)

Related citations, access restricted:

62. Ferrell CD, et al. "Why Women Don't Return: Nurse Perspectives on Follow-Up Care After Abnormal Cervical Cancer Screening Results in Mississippi's Public Health System." Public Health Nurs. September 12, 2026. PMID 42728889. https://doi.org/10.1111/phn.70186 (free to read, no reuse license)

63. White CB, et al. "'…but look how many lives would have been saved if this was available then' Exploring the acceptability of future Human Papillomavirus self-sampling, and the barriers and facilitators of cervical cancer screening for those with intellectual disabilities in Scotland." Br J Health Psychol. September 2026. PMID 42433007. https://doi.org/10.1111/bjhp.70092 (license unconfirmed)

64. Uwihaye JD, et al. "Barriers and Facilitators Influencing National Scaleup of a Women's Cancer Early Detection Program in Rwanda: Perspectives of Policymakers, Program Leaders, and Clinicians." JCO Glob Oncol. September 24, 2026. PMID 42784785. https://doi.org/10.1200/GO-26-00185 (license unconfirmed)

65. Mazzitelli N, et al. "Prevalence of breast, cervical, and colorectal cancer screening among adults according to disability type and difficulty level, United States, 2021 and 2023." Cancer. September 15, 2026. PMID 42720530. https://doi.org/10.1002/cncr.70557 (free to read, no reuse license)

Better ways to treat precancer and confirm it is gone

Directly referenced:

66. Timis G, et al. "Post-Treatment High-Risk HPV Testing as a "Test of Cure": A Systematic Review." Med Sci (Basel). September 11, 2026. PMID 42783434. https://doi.org/10.3390/medsci14050561

67. Damen JAA, et al. "Macroscopic prediction of cervical dysplasia at colposcopy for see-and-treat patient selection: a systematic review." Eur J Obstet Gynecol Reprod Biol. September 2026. PMID 42492476. https://doi.org/10.1016/j.ejogrb.2026.115330

68. Arroyo Mühr LS, et al. "International Papillomavirus Society statement on reputed treatments for human papillomavirus infection and human papillomavirus-related diseases: evidence, risks, and standards for clinical evaluation." Int J Gynecol Cancer. September 1, 2026. PMID 42680631. https://doi.org/10.1016/j.ijgc.2026.104950

69. Stosic M, et al. "Inferred functional microbiome features are associated with clinical trajectories of low-grade cervical lesions." BMC Microbiol. September 12, 2026. PMID 42732072. https://doi.org/10.1186/s12866-026-05648-7

Additional open-access citations:

70. Arnholdt M, et al. "Preclinical Characterization of Dielectric Barrier Discharge as a Complementary Plasma Technology for Low-Thermal Argon Plasma Devitalization of Cervical Intraepithelial Neoplasia." ACS Appl Mater Interfaces. September 9, 2026. PMID 42678941. https://doi.org/10.1021/acsami.6c13697 (open access, preclinical plasma device for precancer treatment)

Related citations, access restricted:

71. Pareja R, et al. "FIGO/IGCS Statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions." Int J Gynecol Cancer. September 1, 2026. PMID 42680632. https://doi.org/10.1016/j.ijgc.2026.104946 (subscription access)

72. Pareja R, et al. "FIGO/IGCS statement on the efficacy of topical treatments for high-risk human papillomavirus in preventing CIN 3+ lesions." Int J Gynaecol Obstet. September 1, 2026. PMID 42677467. https://doi.org/10.1002/ijgo.71285 (subscription access)

73. Ling Y, et al. "[Clinical observational study on detection and treatment of adenocarcinoma in situ of the cervix]." Zhonghua Fu Chan Ke Za Zhi. September 25, 2026. PMID 42802114. https://doi.org/10.3760/cma.j.cn112141-20260210-00100 (license unconfirmed)

74. Wang Q, et al. "[Analysis of risk factors for pathological upgrading after cervical conization in patients with CIN1]." Zhonghua Fu Chan Ke Za Zhi. September 25, 2026. PMID 42802113. https://doi.org/10.3760/cma.j.cn112141-20260224-00109 (license unconfirmed)

75. Mashhadi Abolghasem Shirazi M. "NF-κB signaling in persistent high-risk cervical HPV infection: Clinical evidence, molecular mechanisms, and translational therapeutic opportunities." Int Rev Immunol. September 28, 2026. PMID 42804243. https://doi.org/10.1080/08830185.2026.2736241 (subscription access)

Women living with HIV carry a higher risk, and research is tailoring prevention and care to them

Directly referenced:

76. Meng X, et al. "Estimates of the global burden of HIV-attributable and all-cause AIDS-defining cancers: a population-based modeling study." Front Public Health. September 10, 2026. PMID 42787431. https://doi.org/10.3389/fpubh.2026.1933709

77. Doto D, et al. "Adherence to follow-up cervical cancer screening and its predictors among women living with HIV in Moshi municipality, Tanzania: a hospital-based retrospective cohort study (2019-2024)." BMJ Open. September 15, 2026. PMID 42744367. https://doi.org/10.1136/bmjopen-2025-113748

78. Neze-Sebakunzi J, et al. "Prevalence, high-risk HPV type profile, and factors associated with high-risk HPV infection among women living with HIV in Kinshasa, Democratic Republic of the Congo." Front Public Health. September 18, 2026. PMID 42827944. https://doi.org/10.3389/fpubh.2026.1914799

79. Huang L, et al. "HIV-associated immune remodeling in cervical cancer: implications for immunotherapy, biomarkers, and trial design." Front Immunol. September 14, 2026. PMID 42807817. https://doi.org/10.3389/fimmu.2026.1953030

Additional open-access citations:

80. Pellegrino RA, et al. "Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium." Int J Cancer. September 2026. PMID 41992467. https://doi.org/10.1002/ijc.70503 (open access, cancer screening at HIV clinics worldwide)

81. Jiba DF, et al. "Caregiver knowledge and Attitudes toward Human Papillomavirus Vaccination among adolescent girls living with HIV in Sierra Leone: A health facility-based cross-sectional study." medRxiv. September 23, 2026. PMID 42818422. https://doi.org/10.64898/2026.09.21.26363609 (open access, caregiver HPV vaccine attitudes, girls living with HIV, Sierra Leone; preprint)

Related citations, access restricted:

82. Ceesay E, et al. "Integrating Cervical Cancer Prevention into HIV Services in Sub-Saharan Africa: A Narrative Review Addressing the Dual Burden Among Women." Open Forum Infect Dis. September 9, 2026. PMID 42719686. https://doi.org/10.1093/ofid/ofag509 (restricted license, CC BY-NC-ND 4.0)

83. Lin YC, et al. "Predictors of anal and cervical cancer screening uptake among adults with and without HIV: survey of a community-based health clinic network." Cancer Causes Control. September 9, 2026. PMID 42714682. https://doi.org/10.1007/s10552-026-02239-9 (license unconfirmed)

84. Karlsen E, et al. "Rationale and design of a clinical trial of a reduced dosing schedule for the nonavalent human papillomavirus vaccine in women living with HIV: The NOVA-HIV study." Contemp Clin Trials. September 15, 2026. PMID 42744154. https://doi.org/10.1016/j.cct.2026.108475 (subscription access)

Closing the global equity gap remains central to eliminating cervical cancer

Directly referenced:

85. Sriram S. "Vaccinating girls, abandoning women: the financing asymmetry between HPV immunization and the cervical cancer treatment cascade in low- and middle-income countries." Front Oncol. September 15, 2026. PMID 42812370. https://doi.org/10.3389/fonc.2026.1941545

86. Balasubramani L, et al. "From evidence to implementation: a policy and health systems roadmap for cervical cancer elimination in India." Front Public Health. September 18, 2026. PMID 42827832. https://doi.org/10.3389/fpubh.2026.1906243

87. Liu J, et al. "Declining trends but persistent disparities in cervical cancer mortality in the United States, 1999-2023." Front Public Health. September 3, 2026. PMID 42813077. https://doi.org/10.3389/fpubh.2026.1892243

88. Neethling GS, et al. "From Pap Test to Treatment: Assessing Facility Level Gaps in Cervical Cancer Care in Cape Town." Public Health Chall. September 4, 2026. PMID 42701338. https://doi.org/10.1002/puh2.70360

Additional open-access citations:

89. Aminu K, et al. "Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review." Health Sci Rep. September 25, 2026. PMID 42799168. https://doi.org/10.1002/hsr2.73254 (open access, HPV vaccine financing in Africa, scoping review)

90. Esteire I, et al. "Cervical cancer screening in Sub-Saharan Africa: A scoping review of test and treat and test, triage and treat approaches." Public Health. September 13, 2026. PMID 42732708. https://doi.org/10.1016/j.puhe.2026.106445 (open access, screen-and-treat approaches in Sub-Saharan Africa, scoping review)

91. Pungartnik PC, et al. "Premature mortality and years of potential productive life lost due to HPV-attributable cancers in Brazil and Mexico: 2011 Versus 2023." Hum Vaccin Immunother. September 9, 2026. PMID 42714298. https://doi.org/10.1080/21645515.2026.2728247 (open access, premature deaths from HPV-related cancers, Brazil and Mexico)

92. Guo T, et al. "Global burden of disease attributable to unsafe sex among adults aged 60 years and older, 1990-2023: a secondary analysis of the global burden of disease study 2023." Ann Med. September 23, 2026. PMID 42776971. https://doi.org/10.1080/07853890.2026.2732700 (open access, global burden linked to unsafe sex in adults 60 and older)

93. Frank A, et al. "Understanding the association between immune-modulating helminths and HPV or cervical cancer: A scoping review." PLoS Negl Trop Dis. September 2, 2026. PMID 42685064. https://doi.org/10.1371/journal.pntd.0013308 (open access, helminth infections and HPV, scoping review)

Related citations, access restricted:

94. Setiawati D, et al. "Gynecologic cancers in low- and middle-income countries: Bridging the survival gap." Cancer. September 1, 2026. PMID 42634487. https://doi.org/10.1002/cncr.70518 (free to read, no reuse license)

95. Paz-Soldan VA, et al. "Delivering cervical cancer screening and management to women in remote communities of the Peruvian Amazon: a mixed methods analysis of a mobile point-of-care intervention." Lancet Reg Health Am. September 2026. PMID 42395932. https://doi.org/10.1016/j.lana.2026.101535 (restricted license, CC BY-NC-ND 4.0)

96. Serikova-Esengeldina D, et al. "Global Trends and Disparities in Cervical Cancer Control in Central Asia (1990-2023): A Comparative Age-Period-Cohort and Joinpoint Regression Analysis." Asian Pac J Cancer Prev. September 1, 2026. PMID 42808398. https://doi.org/10.31557/APJCP.2026.27.9.3307 (license unconfirmed)

97. Yuan XH, et al. "[Analysis of the global disease burden of cervical cancer in women aged 65 years and older based on the global burden of disease database]." Zhonghua Yu Fang Yi Xue Za Zhi. September 6, 2026. PMID 42736147. https://doi.org/10.3760/cma.j.cn112150-20260207-00118 (license unconfirmed)

98. Zhang X, et al. "Cervical, Uterine, and Ovarian Cancers in Chinese Women Aged 55 Years and Older: Burden, Temporal Trends, Risk Attribution, and Future Projections From the Global Burden of Disease Study 2021." J Obstet Gynaecol Res. September 2026. PMID 42755024. https://doi.org/10.1111/jog.70413 (subscription access)

Survivorship research is mapping the needs that follow treatment

Directly referenced:

99. Derese BD, et al. "Supportive care needs among patients with breast and cervical cancer at a tertiary cancer treatment center in ethiopia: a cross-sectional study." Sci Rep. September 2, 2026. PMID 42686973. https://doi.org/10.1038/s41598-026-67983-z

100. da Silva-Filho AL, et al. "Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age." Int J Gynaecol Obstet. September 2026. PMID 42483786. https://doi.org/10.1002/ijgo.71188

Related citations, access restricted:

101. Powell J, et al. "Treatment-related Risk of Urologic Adverse Events in Cervical Cancer Survivors." Urology. September 2026. PMID 42289201. https://doi.org/10.1016/j.urology.2026.06.016 (free to read, no reuse license)

102. Jing S, et al. "The Effectiveness of a 6-Week Online Mindfulness-Based Intervention on Patients With Cervical Cancer or High-Grade Squamous Intraepithelial Lesion: A Randomized Controlled Trial Using Multimodal Data of Scales and Electroencephalogram." Psychooncology. September 2026. PMID 42800049. https://doi.org/10.1002/pon.70610 (subscription access)

103. Ahn SY, et al. "Experiences and challenges of North Korean defectors with cervical cancer: a qualitative study using thematic analysis." Support Care Cancer. September 3, 2026. PMID 42690438. https://doi.org/10.1007/s00520-026-11143-6 (subscription access)

104. Rubagumya F, et al. "Decentralizing Post-Treatment Follow-Up for Cervical Cancer in Rwanda: Perspectives of Survivors and Clinicians." JCO Glob Oncol. September 17, 2026. PMID 42753200. https://doi.org/10.1200/GO-26-00131 (license unconfirmed)

105. Gatta G, et al. "Cancer Patients Mortality From Other Causes: A European Population-Based Study." Cancer Med. September 2026. PMID 42734108. https://doi.org/10.1002/cam4.72266 (restricted license, CC BY-NC-ND 4.0)

General and basic-science research continues to map how cervical tumors grow and resist treatment

Additional open-access citations:

106. Bai L, et al. "Hyperthermia sensitizes cervical cancer to chemoradiotherapy by downregulating c-Myc/WSB1/β-catenin expression." Int J Hyperthermia. September 7, 2026. PMID 42703635. https://doi.org/10.1080/02656736.2026.2713197 (open access, hyperthermia and chemoradiation, laboratory study)

107. Ghosh S, et al. "A quantitative treatment assessment for optimizing combined virotherapy-chemotherapy regimens against HPV-induced cervical cancer." PLoS One. September 21, 2026. PMID 42766698. https://doi.org/10.1371/journal.pone.0342672 (open access, mathematical model of virotherapy with chemotherapy)

108. Gbala ID, et al. "Phosphorylated HPV‑16 E7 disrupts planar cell polarity in cervical cancer cells through vangl1 dysregulation." PLoS Pathog. September 21, 2026. PMID 42766580. https://doi.org/10.1371/journal.ppat.1014555 (open access, HPV16 E7 and cell polarity, laboratory study)

109. Mai Q, et al. "Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer." BMC Cancer. September 18, 2026. PMID 42760508. https://doi.org/10.1186/s12885-026-16914-2 (open access, immune-suppressing myeloid cells, laboratory study)

110. Luo X, et al. "Low-Dose Paclitaxel Combined with Dehydrocavidine Synergistically Suppresses Cervical Cancer by Inhibiting FASN/SCD1-Mediated Lipid Metabolism." Biomolecules. September 17, 2026. PMID 42793186. https://doi.org/10.3390/biom16091354 (open access, low-dose paclitaxel combination, laboratory study)

111. Ayağ ME, et al. "Epigallocatechin Gallate Modulates the Cellular Response to Doxorubicin in HeLa Cervical Cancer Cells." Biomolecules. September 8, 2026. PMID 42793131. https://doi.org/10.3390/biom16091299 (open access, green tea compound with doxorubicin, laboratory study)

112. Zhou YN, et al. "Infection and α-ketoglutarate/oxygen inhibition converge to CDC20 to promote cancer cell aneuploidy." Signal Transduct Target Ther. September 4, 2026. PMID 42693088. https://doi.org/10.1038/s41392-026-02956-2 (open access, hypoxia, infection, and chromosome instability)

113. Liu J, et al. "Targeting the KIFC1-SRSF3-PKM Axis Suppresses Cervical Cancer Glycolysis and Enhances Radiosensitivity." J Cell Mol Med. September 2026. PMID 42764482. https://doi.org/10.1111/jcmm.71373 (open access, tumor metabolism and radiosensitivity, laboratory study)

114. Zheng P, et al. "Psychiatric disorders and gynecologic tumors: A 2-sample Mendelian randomization study of 20 exposure-outcome pairs." Medicine (Baltimore). September 18, 2026. PMID 42760730. https://doi.org/10.1097/MD.0000000000050669 (open access, psychiatric disorders and gynecologic cancer risk, genetic study)

Related citations, access restricted:

115. Li N, et al. "Targeting mitochondrial G-quadruplex DNA with a theragnostic small molecule for cervical Cancer imaging and therapy." Spectrochim Acta A Mol Biomol Spectrosc. September 14, 2026. PMID 42759413. https://doi.org/10.1016/j.saa.2026.128793 (subscription access)

116. Wu Y, et al. "RSRC1 is a candidate progression-associated biomarker in cervical cancer linked to p53/CDK2-associated cell-cycle signaling." Eur J Pharmacol. September 19, 2026. PMID 42762908. https://doi.org/10.1016/j.ejphar.2026.179352 (subscription access)

117. Li M, et al. "Molecular epidemiology and phylogeographic architecture of oncogenic intracellular bacteria in cervical cancer patients across Northern China." Infect Genet Evol. September 5, 2026. PMID 42700938. https://doi.org/10.1016/j.meegid.2026.106016 (subscription access)

118. Nyalambisa A, et al. "Interaction of circular RNAs with splicing factors in cervical cancer: Modulation, interplay and theranostics (Review)." Mol Med Rep. September 4, 2026. PMID 42695432. https://doi.org/10.3892/mmr.2026.14006 (restricted license, CC BY-NC-ND 4.0)

119. Feng C, et al. "Tumor cell membrane‑coated MOF‑199 nanoparticles co‑loaded with auranofin and celecoxib enhance single‑dose radiotherapy and anti‑PD‑L1 therapy in cervical cancer." J Nanobiotechnology. September 25, 2026. PMID 42816842. https://doi.org/10.1186/s12951-026-05116-4 (restricted license, CC BY-NC-ND 4.0)

120. Chen R, et al. "[Inhibition of RBM5 expression by the interaction between hsa_circ_0006200 and EIF4A3 and its impact on cervical cancer progression]." Zhonghua Fu Chan Ke Za Zhi. September 25, 2026. PMID 42802115. https://doi.org/10.3760/cma.j.cn112141-20260402-00180 (license unconfirmed)

121. Xie Z, et al. "DNAJC9 promotes cervical cancer cell proliferation by regulating GLI1 expression." Acta Biochim Biophys Sin (Shanghai). September 25, 2026. PMID 42185231. https://doi.org/10.3724/abbs.2026080 (license unconfirmed)

122. Liu L, et al. "Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets." Daru. September 21, 2026. PMID 42766055. https://doi.org/10.1007/s40199-026-00660-8 (subscription access)

123. Navya VB, et al. "A prognostic immune signaling-related lncRNA-circRNA-mRNA network model for cervical cancer using machine learning." Biochem Biophys Res Commun. September 2026. PMID 42508130. https://doi.org/10.1016/j.bbrc.2026.154337 (subscription access)

124. Fei Y, et al. "Targeting cellular senescence in cervical Cancer: a novel pathway to preserve reproductive potential." Int Immunopharmacol. September 2026. PMID 42308794. https://doi.org/10.1016/j.intimp.2026.117005 (subscription access)

125. Modi A, et al. "LiCl induces GSK-3β mediated autophagy, DNA damage, and cell cycle arrest in HPV driven cervical cancer cells." Cancer Chemother Pharmacol. September 12, 2026. PMID 42730788. https://doi.org/10.1007/s00280-026-04956-z (subscription access)

126. Wang Q, et al. "Regulating the activity of cervical cancer cells through electrochemical modulation of membrane-surface redox states." Chem Commun (Camb). September 11, 2026. PMID 42606501. https://doi.org/10.1039/d6cc04339a (subscription access)

127. Horiuchi Y, et al. "Xanthoangelol, a chalcone from Angelica keiskei, induces apoptosis in cervical cancer cell lines via the oxidative stress-mediated activation of caspase-8 and caspase-9." Biochem Biophys Res Commun. September 2026. PMID 42398337. https://doi.org/10.1016/j.bbrc.2026.154209 (subscription access)

128. Zhang Y, et al. "GMPS promotes cervical squamous cell carcinoma cell immune evasion through USP7-mediated deubiquitination of PDL1." Hum Cell. September 7, 2026. PMID 42704520. https://doi.org/10.1007/s13577-026-01447-4 (subscription access)

129. Santos ABC, et al. "Emerging Insights into Comparative Genetic Mutations in HPV-Associated and HPV-Independent Cervical Cancer: A Systematic Review." Asian Pac J Cancer Prev. September 1, 2026. PMID 42808379. https://doi.org/10.31557/APJCP.2026.27.9.3139 (license unconfirmed)

130. Shen HP, et al. "Integrated Genomic Profiling of PTEN and TP53 in Cervical Neuroendocrine Carcinoma: Synergistic Roles With HER2/KRAS/PIK3CA and Implications for Precision Oncology." Genes Chromosomes Cancer. September 2026. PMID 42765697. https://doi.org/10.1002/gcc.70173 (subscription access)

131. Robinson EW, et al. "STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma." Cancer Med. September 2026. PMID 42702935. https://doi.org/10.1002/cam4.72228 (restricted license, CC BY-NC-ND 4.0)

132. Karekar AK, et al. "Stage-specific lipidomic signatures as biomarkers in progression of cervical cancer." Indian J Med Res. September 2026. PMID 42690850. https://doi.org/10.25259/IJMR_3238_2025 (restricted license, CC BY-NC-SA 4.0)

133. Tawfeek HM, et al. "Spotlights on Cervical Cancer: Progression, Diagnosis and Clinical Manifestations, Epidemiology, Treatment Approaches, Role of Artificial Intelligence and Future Directions." Drug Dev Ind Pharm. September 28, 2026. PMID 42803760. https://doi.org/10.1080/03639045.2026.2741083 (subscription access)

A note on how this digest was made: This edition was built by searching PubMed for papers published in September 2026, using a two-tier strategy: targeted thematic searches across the cervical cancer landscape (treatment, immunotherapy, antibody-drug conjugates, HPV vaccination, screening, disparities, surgery, molecular subtypes, precancer, survivorship, and rare subtypes), plus a dedicated qualitative search and a broad MeSH sweep. Papers summarized in full are open access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.